INTERCEPT Blood System Kit Shipments Surpass 7.5 Million Treatable Platelet and Plasma Doses Since Launch
William ‘Obi’ Greenman, Cerus’ president and chief executive officer explains, “This is a significant milestone for Cerus and highlights the scope our technology has had within the transfusion industry and on the millions of patients worldwide transfused with INTERCEPT treated platelet and plasma components. “We have a solid track record with the safety and efficacy of our INTERCEPT products, which now surpasses more than 7.5 million treatable doses.”
Cerus Corporation Announces FDA Approval for INTERCEPT Blood System for Plasma with Alternate Plastic Disposable Kits
The planned conversion to these new kits is part of the Company’s ongoing strategy to enhance its global supply chain integrity that was initiated several years ago.
CE Mark approval was based on data generated from the company's two EU studies evaluating the safety and efficacy of the Contour Neurovascular System™, focusing on unruptured intracranial aneurysms.
12/19/18: ReCePI is designed to evaluate the efficacy and safety of INTERCEPT RBCs in patients requiring transfusion for acute blood loss during complex cardiac surgery. A total of 600 patients are expected to be enrolled in up to 20 participating sites in the U.S.
Cerus Announces the Fourth Biologics License Application (BLA) Approval for a U.S. Blood Center Customer
3/13/18: “CBC Appleton’s BLA approval is another important step in our mission to make INTERCEPT the standard of care for transfused blood components,” said William “Obi” Greenman, Cerus’ president and chief executive officer.